CanSino Biologics


CanSino Biologics, often abbreviated as CanSinoBIO, is a Chinese vaccine company.

History

CanSino Biologics was founded in 2009 in Tianjin, China by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.
In July 2018, it filed an application to list on the Hong Kong Stock Exchange. It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017.

Vaccines

The company has a portfolio of vaccines under research including Ad5-EBOV to prevent Ebola and Ad5-nCoV for COVID-19. Both are developed jointly with the Institute of Biotechnology of the Academy of Military Medical Sciences of the People's Liberation Army.
The company has also collaborated with the National Research Council of Canada on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.
In March 2020, CanSino made a deal to collaborate with the NRC on development of the COVID-19 vaccine candidate Ad5-nCoV, to help end the COVID-19 pandemic, with plans to conduct a clinical trial in Canada. Ad5-nCoV was the first COVID-19 vaccine candidate in the world to begin Phase II human trials.
In early July, CanSino Biologics began talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, with the company planning to recruit 40,000 participants for the test. Co-Founder Qiu Dongxu said its Phase II trial involving 508 people has yielded “much better” results than the Phase I about the safety and ability to trigger immune response but did not disclose specific evidence.

Investors

CanSino Biologics investors included Lilly Asia Ventures, Qiming Venture Partners and SDIC Fund Management.